Teva, Institutional and private investors to purchase MediWound
shares for 30 Million USD (Pre-money valuation: $100 Million)
June 2007 (Hebrew) (English)

Non-binding term sheet signed with strategic investor for $15 Million
(Pre-money valuation: $100 Million)
December 2006 (Hebrew) Click Here

MediWound is entering a Phase III clinical trial
February 2006 Click Here